255 related articles for article (PubMed ID: 29722028)
1. Emerging disease-modifying strategies targeting α-synuclein for the treatment of Parkinson's disease.
O'Hara DM; Kalia SK; Kalia LV
Br J Pharmacol; 2018 Aug; 175(15):3080-3089. PubMed ID: 29722028
[TBL] [Abstract][Full Text] [Related]
2. Ferroptosis and cell death mechanisms in Parkinson's disease.
Guiney SJ; Adlard PA; Bush AI; Finkelstein DI; Ayton S
Neurochem Int; 2017 Mar; 104():34-48. PubMed ID: 28082232
[TBL] [Abstract][Full Text] [Related]
3. α-Synuclein BAC transgenic mice exhibit RBD-like behaviour and hyposmia: a prodromal Parkinson's disease model.
Taguchi T; Ikuno M; Hondo M; Parajuli LK; Taguchi K; Ueda J; Sawamura M; Okuda S; Nakanishi E; Hara J; Uemura N; Hatanaka Y; Ayaki T; Matsuzawa S; Tanaka M; El-Agnaf OMA; Koike M; Yanagisawa M; Uemura MT; Yamakado H; Takahashi R
Brain; 2020 Jan; 143(1):249-265. PubMed ID: 31816026
[TBL] [Abstract][Full Text] [Related]
4. CD8 T cell nigral infiltration precedes synucleinopathy in early stages of Parkinson's disease.
Galiano-Landeira J; Torra A; Vila M; Bové J
Brain; 2020 Dec; 143(12):3717-3733. PubMed ID: 33118032
[TBL] [Abstract][Full Text] [Related]
5. Dopamine-dependent early synaptic and motor dysfunctions induced by α-synuclein in the nigrostriatal circuit.
Tozzi A; Sciaccaluga M; Loffredo V; Megaro A; Ledonne A; Cardinale A; Federici M; Bellingacci L; Paciotti S; Ferrari E; La Rocca A; Martini A; Mercuri NB; Gardoni F; Picconi B; Ghiglieri V; De Leonibus E; Calabresi P
Brain; 2021 Dec; 144(11):3477-3491. PubMed ID: 34297092
[TBL] [Abstract][Full Text] [Related]
6. Depopulation of dense α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson's disease model.
Wegrzynowicz M; Bar-On D; Calo' L; Anichtchik O; Iovino M; Xia J; Ryazanov S; Leonov A; Giese A; Dalley JW; Griesinger C; Ashery U; Spillantini MG
Acta Neuropathol; 2019 Oct; 138(4):575-595. PubMed ID: 31165254
[TBL] [Abstract][Full Text] [Related]
7. Rasagiline and selegiline modulate mitochondrial homeostasis, intervene apoptosis system and mitigate α-synuclein cytotoxicity in disease-modifying therapy for Parkinson's disease.
Naoi M; Maruyama W; Shamoto-Nagai M
J Neural Transm (Vienna); 2020 Feb; 127(2):131-147. PubMed ID: 31993732
[TBL] [Abstract][Full Text] [Related]
8. Disease-modifying treatment of Parkinson's disease by phytochemicals: targeting multiple pathogenic factors.
Naoi M; Maruyama W; Shamoto-Nagai M
J Neural Transm (Vienna); 2022 Jun; 129(5-6):737-753. PubMed ID: 34654977
[TBL] [Abstract][Full Text] [Related]
9. α-Synuclein O-GlcNAcylation alters aggregation and toxicity, revealing certain residues as potential inhibitors of Parkinson's disease.
Levine PM; Galesic A; Balana AT; Mahul-Mellier AL; Navarro MX; De Leon CA; Lashuel HA; Pratt MR
Proc Natl Acad Sci U S A; 2019 Jan; 116(5):1511-1519. PubMed ID: 30651314
[TBL] [Abstract][Full Text] [Related]
10. Alpha-synuclein and iron: two keys unlocking Parkinson's disease.
Lingor P; Carboni E; Koch JC
J Neural Transm (Vienna); 2017 Aug; 124(8):973-981. PubMed ID: 28168622
[TBL] [Abstract][Full Text] [Related]
11. Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations.
Dehay B; Bourdenx M; Gorry P; Przedborski S; Vila M; Hunot S; Singleton A; Olanow CW; Merchant KM; Bezard E; Petsko GA; Meissner WG
Lancet Neurol; 2015 Aug; 14(8):855-866. PubMed ID: 26050140
[TBL] [Abstract][Full Text] [Related]
12. Pathological and clinical aspects of alpha/beta synuclein in Parkinson's disease and related disorders.
Tolmasov M; Djaldetti R; Lev N; Gilgun-Sherki Y
Expert Rev Neurother; 2016 May; 16(5):505-13. PubMed ID: 26959397
[TBL] [Abstract][Full Text] [Related]
13. Defining α-synuclein species responsible for Parkinson's disease phenotypes in mice.
Froula JM; Castellana-Cruz M; Anabtawi NM; Camino JD; Chen SW; Thrasher DR; Freire J; Yazdi AA; Fleming S; Dobson CM; Kumita JR; Cremades N; Volpicelli-Daley LA
J Biol Chem; 2019 Jul; 294(27):10392-10406. PubMed ID: 31142553
[TBL] [Abstract][Full Text] [Related]
14. Slowing Parkinson's Disease Progression with Vaccination and Other Immunotherapies.
Vijayakumar D; Jankovic J
CNS Drugs; 2022 Apr; 36(4):327-343. PubMed ID: 35212935
[TBL] [Abstract][Full Text] [Related]
15. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
[TBL] [Abstract][Full Text] [Related]
16. α-Synuclein in Parkinson's disease: pathogenic function and translation into animal models.
Eschbach J; Danzer KM
Neurodegener Dis; 2014; 14(1):1-17. PubMed ID: 24080741
[TBL] [Abstract][Full Text] [Related]
17. [Relationship between Drug Metabolism and Intestinal Microbiota in Parkinson's Disease].
Hirayama M; Ohno K; Katsuno M
Brain Nerve; 2020 Jul; 72(7):805-809. PubMed ID: 32641577
[TBL] [Abstract][Full Text] [Related]
18. Methods for detecting toxic α-synuclein species as a biomarker for Parkinson's disease.
O'Hara DM; Kalia SK; Kalia LV
Crit Rev Clin Lab Sci; 2020 Aug; 57(5):291-307. PubMed ID: 32116096
[TBL] [Abstract][Full Text] [Related]
19. An update on new-age potential biomarkers for Parkinson's disease.
Soni R; Mathur K; Shah J
Ageing Res Rev; 2024 Feb; 94():102208. PubMed ID: 38296162
[TBL] [Abstract][Full Text] [Related]
20. Initiation and propagation of α-synuclein aggregation in the nervous system.
Hijaz BA; Volpicelli-Daley LA
Mol Neurodegener; 2020 Mar; 15(1):19. PubMed ID: 32143659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
